Advertisement

From the Overview to the Patient: How To Interpret Meta-analysis Data

  • R. D. Gelber
  • A. Goldhirsch
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 127)

Abstract

Clinical investigators have not easily accepted the concept of meta-analysis. Those who perform these formal statistical combinations of data from several different trials have been referred to as “those burgeoning band of interlopers, the meta-analysts” [1]. Critics have referred to meta-analysis as “pooling, drowning, and floating” in the past [2], and even today many view the exercise as potentially dangerous, and clearly a threat to the integrity and importance of the individual clinical trial [3, 4].

Keywords

Estrogen Receptor Endocrine Therapy Estrogen Receptor Status Indirect Comparison Early Breast Cancer Trialist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Horton R (1991) Conference report: double dealing with your data. Lancet 337:784–785CrossRefGoogle Scholar
  2. 2.
    Goldman L, Feinstein AR (1979) Anticoagulants and myocardial infarction: the problems of pooling, drowning, and floating. Ann Intern Med 90:92–94PubMedGoogle Scholar
  3. 3.
    Wachter K (1988) Disturbed by meta-analysis? Science 241:1407–1408PubMedCrossRefGoogle Scholar
  4. 4.
    Mann C (1990) Meta-analysis in the breech. Science 249:476–480PubMedCrossRefGoogle Scholar
  5. 5.
    Early Breast Cancer Trialists’ Collaborative Group (1988) Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28896 women. N Engl J Med 319:1681–1692CrossRefGoogle Scholar
  6. 6.
    Gelber RD, Goldhirsch A (1986) The concept of an overview of cancer clinical trials with special emphasis on early breast cancer. J Clin Oncol 4:1696–1703PubMedGoogle Scholar
  7. 7.
    Gelber RD, Goldhirsch A (1987) The evaluation of subsets in meta-analysis. Stat Med 6:371–388PubMedCrossRefGoogle Scholar
  8. 8.
    Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 339:1–15, 71–85Google Scholar
  9. 9.
    Gelber RD, Goldhirsch A, for the International Breast Cancer Study Group (formerly Ludwig Group) (1992) Reporting and interpreting adjuvant therapy clinical trials. J Natl Cancer Inst Monogr 11:175–180Google Scholar
  10. 10.
    Altman LK (1992) Study on breast cancer finds therapy is effective for years. New York Times, Jan 4Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1993

Authors and Affiliations

  • R. D. Gelber
    • 1
  • A. Goldhirsch
    • 2
  1. 1.Harvard Medical School, Harvard School of Public HealthDana-Farber Cancer InstituteBostonUSA
  2. 2.International Breast Cancer Study GroupOspedale CivicoLuganoSwitzerland

Personalised recommendations